Risk of inflammatory bowel disease following hospitalisation with infectious mononucleosis: nationwide cohort study from Denmark.
Humans
Denmark
/ epidemiology
Infectious Mononucleosis
/ epidemiology
Male
Female
Adult
Adolescent
Hospitalization
/ statistics & numerical data
Child
Cohort Studies
Child, Preschool
Inflammatory Bowel Diseases
/ epidemiology
Young Adult
Infant
Risk Factors
Colitis, Ulcerative
/ epidemiology
Middle Aged
Infant, Newborn
Crohn Disease
/ epidemiology
Chlamydia Infections
/ epidemiology
Chlamydia trachomatis
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
09
04
2024
accepted:
27
08
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
27
9
2024
Statut:
epublish
Résumé
Infectious mononucleosis (IM) is suspected to be associated with inflammatory bowel disease (IBD) development. Using a Danish nationwide cohort of people developing severe IM and their age-, sex-, and socioeconomic (SES) index-matched counterparts, we investigated the subsequent risk of IBD, Crohn's disease (CD), or ulcerative colitis (UC) development from 1977 to 2021. Among 39,684 severe IM patients we find a sex-, age-, and SES index-adjusted HR for IBD of 1.35 (95% CI: 1.22-1.49). This significantly increased risk was seen for both CD (HR: 1.56; 95% CI: 1.34-1.83) and to a lesser extent UC (HR: 1.23; 95% CI: 1.08-1.40) and remains following negative control matching with a cohort diagnosed with Chlamydia trachomatis infection (HR: 1.39; 95% CI: 1.01-1.91). Those with severe IM at 0-9 years had a particularly increased risk for CD (HR: 1.77; 95% CI: 1.26-2.49). Here we show an increased risk for IBD diagnosis following IM hospitalisation, indicating an association between severe EBV disease and later IBD development. Further exploration of the potential factors contributing to IBD susceptibility following EBV disease is warranted.
Identifiants
pubmed: 39333475
doi: 10.1038/s41467-024-52195-8
pii: 10.1038/s41467-024-52195-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8383Subventions
Organisme : Lundbeckfonden (Lundbeck Foundation)
ID : R403-2022-1531
Organisme : Novo Nordisk Fonden (Novo Nordisk Foundation)
ID : NNF21OC0068631
Organisme : Danmarks Grundforskningsfond (Danish National Research Foundation)
ID : DNRF148
Informations de copyright
© 2024. The Author(s).
Références
Alatab, S. et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 17–30 (2020).
doi: 10.1016/S2468-1253(19)30333-4
Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769–2778 (2017).
doi: 10.1016/S0140-6736(17)32448-0
pubmed: 29050646
Larsen, L. et al. Has the incidence of inflammatory bowel disease peaked? Evidence from the population-based NorDIBD cohort 1978–2020. Am. J. Gastroenterol. 118, 501–510 (2023).
doi: 10.14309/ajg.0000000000002187
pubmed: 36728238
Chang, J. T. Pathophysiology of inflammatory bowel diseases. N. Engl. J. Med. 383, 2652–2664.
de Souza, H. S. & Fiocchi, C. Immunopathogenesis of IBD: current state of the art. Nat. Rev. Gastroenterol. Hepatol. 13, 13–27 (2015). 2015 131.
doi: 10.1038/nrgastro.2015.186
pubmed: 26627550
Piovani, D. et al. Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology 157, 647–659.e4 (2019).
doi: 10.1053/j.gastro.2019.04.016
pubmed: 31014995
Pazmandi, J. et al. Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms. Immunol. Rev. 287, 162–185 (2019).
doi: 10.1111/imr.12726
pubmed: 30565237
Mann, E. A. & Saeed, S. A. Gastrointestinal infection as a trigger for inflammatory bowel disease. Curr. Opin. Gastroenterol. 28, 24–29 (2012).
doi: 10.1097/MOG.0b013e32834c453e
pubmed: 22080823
Hutchinson, E. Risk of IBD increases after Salmonella or Campylobacter gastroenteritis. Nat. Rev. Gastroenterol. Hepatol. 6, 561–561 (2009). 610 2009.
doi: 10.1038/nrgastro.2009.152
Jess, T. et al. Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. Gut 60, 318–324 (2011).
doi: 10.1136/gut.2010.223396
pubmed: 21193449
Lidar, M. et al. Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role. Ann. N Y Acad. Sci. 1173, 640–648 (2009).
doi: 10.1111/j.1749-6632.2009.04673.x
pubmed: 19758210
James, R. R. Infectious mononucleosis: epidemiology and pathophysiology. Emerg. Med. N. 23, 6–10 (2001).
doi: 10.1097/00132981-200104000-00009
Gares, V. et al. The role of the early social environment on Epstein Barr virus infection: a prospective observational design using the millennium cohort study. Epidemiol. Infect. 145, 3405–3412 (2017).
doi: 10.1017/S0950268817002515
pubmed: 29202893
Rostgaard, K. et al. Primary Epstein–Barr virus infection with and without infectious mononucleosis. PLoS One 14, e0226436 (2019).
Kuri, A. et al. Epidemiology of Epstein–Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health 20, 1–9 (2020).
doi: 10.1186/s12889-020-09049-x
Ball, R. J. et al. Systematic review and meta-analysis of the sero-epidemiological association between Epstein–Barr virus and rheumatoid arthritis. Arthritis Res. Ther. 17, 274 (2015).
Houen G., Trier N. H. Epstein–Barr virus and systemic autoimmune diseases. Front. Immunol. 11, 587380 (2021).
Chen, X. et al. Epstein‒Barr virus and human herpesvirus 6 infection in patients with systemic lupus erythematosus. Virol. J. 20, 1–11 (2023).
doi: 10.1186/s12985-023-01987-3
Soldan, S. S. & Lieberman, P. M. Epstein–Barr virus and multiple sclerosis. Nat. Rev. Microbiol. 21, 51–64 (2023).
doi: 10.1038/s41579-022-00770-5
pubmed: 35931816
Bjornevik, K. et al. Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat. Rev. Neurol. 19, :160–:171 (2023). 193 2023.
pubmed: 36759741
Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein–Barr virus associated with multiple sclerosis. Science (80-) 375, 296–301 (2022).
doi: 10.1126/science.abj8222
Nandy, A. et al. 463: EPSTEIN BARR VIRUS (EBV) EXPOSURE PRECEDES CROHN’S DISEASE DEVELOPMENT.Gastroenterology 162, S-105 (2022).
doi: 10.1016/S0016-5085(22)60262-2
Loosen, S. H. et al. Infectious mononucleosis is associated with an increased incidence of Crohn’s disease: results from a cohort study of 31 862 outpatients in Germany. Eur. J. Gastroenterol. Hepatol. 35, 255–260 (2023).
doi: 10.1097/MEG.0000000000002505
pubmed: 36708295
Arendt, J. F. H. et al. Existing data sources in clinical epidemiology: laboratory information system databases in Denmark. Clin. Epidemiol. 12, 469 (2020).
doi: 10.2147/CLEP.S245060
pubmed: 32547238
pmcid: 7244445
Gehlert, T., Devergne, O. & Niedobitek, G. Epstein–Barr virus (EBV) infection and expression of the interleukin-12 family member EBV-induced gene 3 (EBI3) in chronic inflammatory bowel disease. J. Med. Virol. 73, 432–438 (2004).
doi: 10.1002/jmv.20109
pubmed: 15170639
Yanai, H. et al. Epstein–Barr virus infection of the colon with inflammatory bowel disease. Am. J. Gastroenterol. 94, 1582–1586 (1999).
doi: 10.1111/j.1572-0241.1999.01148.x
pubmed: 10364028
Harley, J. B. et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat. Genet. 50, 699–707 (2018). 505 2018.
doi: 10.1038/s41588-018-0102-3
pubmed: 29662164
pmcid: 6022759
Wong, Y. et al. Estimating the global burden of Epstein–Barr virus-related cancers. J. Cancer Res. Clin. Oncol. 148, 31 (2022).
doi: 10.1007/s00432-021-03824-y
pubmed: 34705104
Gequelin, L. C. F. et al. Epstein–Barr virus: general factors, virus-related diseases and measurement of viral load after transplant. Rev. Bras. Hematol. Hemoter. 33, 383 (2011).
doi: 10.5581/1516-8484.20110103
pubmed: 23049344
pmcid: 3415781
Loosen, S. H. et al. Infectious mononucleosis is associated with an increased incidence of multiple sclerosis: results from a cohort study of 32,116 outpatients in Germany. Front. Immunol. 13, 937583 (2022).
doi: 10.3389/fimmu.2022.937583
pubmed: 35983044
pmcid: 9379368
Loosen, S. H. et al. Infectious mononucleosis is associated with an increased incidence of NAFLD. Eur. J. Clin. Invest. 53, e13911 (2023).
doi: 10.1111/eci.13911
pubmed: 36409277
Roderburg, C. et al. The association between infectious mononucleosis and cancer: a cohort study of 24,190 outpatients in Germany. Cancers 14, 5837 (2022).
Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 603, 321–327 (2022). 6037900 2022.
doi: 10.1038/s41586-022-04432-7
pubmed: 35073561
pmcid: 9382663
Garabatos, N. & Santamaria, P. Gut microbial antigenic mimicry in autoimmunity. Front Immunol. 13, 873607 (2022).
doi: 10.3389/fimmu.2022.873607
pubmed: 35572569
pmcid: 9094498
English, J., Patrick, S. & Stewart, L. D. The potential role of molecular mimicry by the anaerobic microbiota in the aetiology of autoimmune disease. Anaerobe 80, 102721 (2023).
doi: 10.1016/j.anaerobe.2023.102721
pubmed: 36940867
Verma, A. et al. Elucidating potential molecular signatures through host-microbe interactions for reactive arthritis and inflammatory bowel disease using combinatorial approach. Sci. Rep. 10, 1–16 (2020). 101 2020.
doi: 10.1038/s41598-020-71674-8
Pender, M. P. et al. Defective T-cell control of Epstein–Barr virus infection in multiplesclerosis. Clin. Transl. Immunol. 6, e126 (2017).
doi: 10.1038/cti.2016.87
Atara Biotherapeutics. Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis. ClinicalTrials.gov identifier NCT03283826. Last Updated 23 Feb 2024. Accessed 17 July 2024. clinicaltrials.gov.
Callan, M. F. C. The immune response to Epstein–Barr virus. Microbes Infect. 6, 937–945 (2004).
doi: 10.1016/j.micinf.2004.04.014
pubmed: 15310471
Horton, R. et al. Gene map of the extended human MHC. Nat. Rev. Genet. 5, 889–899 (2004).
doi: 10.1038/nrg1489
pubmed: 15573121
Fonager, K. et al. Assessment of the diagnoses of Crohn’s disease and ulcerative colitis in a Danish hospital information system. Scand. J. Gastroenterol. 31, 154–159 (1996).
doi: 10.3109/00365529609031980
pubmed: 8658038
Jacobsen, H. A., Jess, T. & Larsen, L. Validity of inflammatory bowel disease diagnoses in the Danish National Patient Registry: a population-based study from the North Denmark region. Clin. Epidemiol. 14, 1099–1109 (2022).
doi: 10.2147/CLEP.S378003
Hedström, A. K. et al. Smoking and Epstein–Barr virus infection in multiple sclerosis development. Sci. Rep. 10, 10960 (2020).
Ho, S.-M. et al. Challenges in IBD research: environmental triggers. Inflamm. Bowel Dis. 25, S13–S23 (2019).
doi: 10.1093/ibd/izz076
pubmed: 31095702
pmcid: 6787673
Rosenbaum, P. R. & Rubin, D. B. The central role of the propensity score in observational studies for causal effects. Biometrika 70, 41–55 (1983).
doi: 10.1093/biomet/70.1.41
Desai, R. J. & Franklin, J. M. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ 367, l5657 (2019).